Erlotinib or docetaxel for second-line treatment of non-small cell lung cancer: A real-world cost-effectiveness analysis

Journal of Thoracic Oncology

Volumn 6, Issue 12, 2011, Pages 2097-2103

  Cromwell, Ian ^a   Van Der Hoek, Kimberly ^a   Melosky, Barbara ^a   Peacock, Stuart ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cost effectiveness; Docetaxel; Erlotinib; Health economics; Lung cancer; Real world; Retrospective analysis

Indexed keywords

DOCETAXEL; ERLOTINIB;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG WITHDRAWAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 81755185472     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31822f657a     Document Type: Article

References (22)

1. Committee, C.C.S.s.S. Canadian Cancer Statistics 2009. 2010. Available at:http://www.cancer.ca/Canada-wide/About%20cancer/Cancer%20statistics/-/media/ CCS/Canada%20wide/Files%20List/English%20files%20heading/ pdf%20not%20in%20publications%20section/Stats%202009E%20Cdn%20Cancer.ashx. Accessed February 2, 2011.
2. Neville A. Lung cancer. Clin Evid 2008;4:1-31.
3. Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previouslytreated non-small-cell lung cancer. N Engl J Med 2005;353:123-132. (Pubitemid 41058344)
4. Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2006;24:3831-3837. (Pubitemid 46630729)
5. Melosky B, Agulnik J, Assi H. Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib. Curr Oncol 2008;15:25-31.
6. Agency BC. BCCA Protocol Summary for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with Erlotinib. 2009. Available at:http://www.bccancer. bc.ca/NR/rdonlyres/5743F797-D252-42DBB689-339C079C904B/38143/ LUAVERL-Protocol-1Aug09.pdf. Accessed February 2, 2011.
7. Agency BC. BCCA Protocol Summary For Second-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with Docetaxel. 2009. Available at:http://www.bccancer.bc.ca/NR/rdonlyres/5743F797-D252-42DB-B689-339C079C904B/ 33153/LUAVDOC-Protocol-1Apr09.pdf.Accessed February 2, 2011.
8. Grønberg BH, Bremmes RM, Fløtten O, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:3217-3224.
9. Lee DH, Park K, Kim JH, et al. Randomized Phase III trial of gefitinib versus docetaxel in non-small-cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 2010; 16:1307-1314.
10. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103. (Pubitemid 30324363)
11. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinolrebine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-2362. (Pubitemid 30415821)
12. Hanna N, Shepherd F, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597. (Pubitemid 41079796)
13. Smit EF, Mattson K, val Pawel J, et al. ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study. Ann Oncol 2003;14:455-460. (Pubitemid 36367425)
14. Ng R, Loreto M, Lee R, et al. Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small-cell lung cancer (nsclc) following failure of platinumbased chemotherapy. Lung Cancer 2008;61:262-265.
15. Leighl NB, Shepherd FA, Kwong R, et al. Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 2002;20: 1344-1352. (Pubitemid 34177441)
16. Ramsey SD, Martins RG, Blough DK, et al. Second-line and third-line chemotherapy for lung cancer: use and cost. Am J Manag Care 2008; 14:297-306.
17. Carlson JJ, Reyes C, Oestreicher N, et al. Comparative clinical and economic outcomes of treatments for refractory non-small-cell lung cancer (NSCLC). Lung Cancer 2008;61:405-415.
18. Araújo A, Parente B, Sotto-Mayor R, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small-cell lung cancer. Rev Port Pneumol 2008;14:803-827.
19. Gatzemeier U, Pirk O, Gabriel A, et al. Second-line-therapy for nonsmall cell lung cancer (NSCLC)-a retrospective cost analysis. Tumordiagn Ther 2008;29:211-217.
20. Lyseng-Williamson KA. Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer. Pharmacoeconomics 2010; 28:75-92.
21. Bradbury PA, Tu D, Seymour L, et al. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. J Natl Cancer Inst 2010;102:298-306.
22. Leighl NB, Tsao WS, Zawisza DL, et al. A willingness-to-pay study of oral epidermal growth factor tyroside kinase inhibitors in advanced non-small-cell lung cancer. Lung Cancer 2006;51:115-121. (Pubitemid 43088631)